OMER, Israel, April 7, 2014 (GLOBE NEWSWIRE) -- Medigus Ltd. (TASE: MDGS), a medical device company developing and commercializing minimally invasive endosurgical tools and procedures, announced two studies on the MUSE(TM) (formerly the SRS(TM)) system were highlighted as oral presentations during the prestigious 2014 Society of American Gastrointestinal and Endoscopic Surgeons (SAGES) Emerging Technology Session in Salt Lake City, Utah. The first study confirmed MUSE as a trans-oral, effective treatment option for Gastroesophageal Reflux Disease (GERD), reporting that in a study of 69 subjects, 85% of patients reduced GERD medication use by >= 50% with 65% of subjects eliminating GERD medication entirely after 6 months. The study also found that 73% of subjects improved quality of life scores by >= 50%. The second study on a swine model explored the feasibility of adding MUSE to address the potential for GERD after performing a per-oral esophageal myotomy (POEM) procedure for achalasia.
Help employers find you! Check out all the jobs and post your resume.
